Tei S, Kigawa J, Okada M, Itamochi H, Kanamori Y, Irie T, Minagawa Y, Terakawa N
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago.
Nihon Sanka Fujinka Gakkai Zasshi. 1996 Oct;48(10):883-7.
The aim of this study was to determine the influence of cytoreductive surgery followed by chemotherapy on quality of life (QOL) in patients with advanced ovarian cancer. A total of 33 patients, who underwent the treatment after telling the truth and gave us the information on QOL 11 to 42 months after the discharge, were entered into the present study. Survival and length of hospital stay were calculated. QOL including emotional and physical well-being were assessed with a structure questionnaire which gives 110 points as full marks. The estimated 5-year survival rate was 49.6%. The mean survival time and length of hospital stay were 1,257 and 382 days, respectively. The mean QOL score was estimated to be 93.2. THe scores for both sociality and mentality showed a tendency to increase after completion of the treatment. Thirty-two of 33 cases (97.0%) obtained a good response for telling the truth. Alopecia and emesis due to chemotherapy were serious problems for patients. The present study showed that telling the truth was useful for well-informed consent and the QOL of patients with advanced ovarian cancer was not disturbed by cytoreductive surgery or chemotherapy.
本研究的目的是确定减瘤手术后化疗对晚期卵巢癌患者生活质量（QOL）的影响。共有33例患者在被告知实情后接受了该治疗，并在出院后11至42个月向我们提供了生活质量信息，纳入本研究。计算生存率和住院时间。使用满分110分的结构化问卷评估包括情绪和身体健康在内的生活质量。估计5年生存率为49.6%。平均生存时间和住院时间分别为1257天和382天。平均生活质量得分为93.2分。社交和心理方面的得分在治疗完成后均有上升趋势。33例中有32例（97.0%）因被告知实情而反应良好。化疗引起的脱发和呕吐是患者面临的严重问题。本研究表明，告知实情有助于获得充分知情同意，晚期卵巢癌患者的生活质量不受减瘤手术或化疗的干扰。
